当前肝癌的局部区域治疗和治疗策略。
Current locoregional therapies and treatment strategies in hepatocellular carcinoma.
机构信息
Department of Medical Imaging, Western University, London, ON.
Department of Radiology, University of British Columbia, Vancouver, BC.
出版信息
Curr Oncol. 2020 Nov;27(Suppl 3):S144-S151. doi: 10.3747/co.27.7171. Epub 2020 Nov 1.
Abstract
Locoregional therapies (lrts) play an important role in the treatment of hepatocellular carcinoma (hcc), with the aim of increasing overall survival while preserving liver function. Various forms of lrt are available, and choosing the best one depends on technical aspects, liver morphology, tumour biology, and the patient's symptoms. The purpose of the present review article is to provide an overview of the current evidence relating to the use of percutaneous ablation, transarterial chemoembolization, and transarterial radioembolization for the curative or palliative treatment of hcc. Special situations are also reviewed, including the combined use of systemic therapy and lrt, indications and techniques for bridging to transplant and downstaging, and the use of lrt to treat patients with hcc and macrovascular invasion.
摘要
局部区域治疗（lrts）在肝细胞癌（hcc）的治疗中起着重要作用，旨在提高总体生存率的同时保留肝功能。有多种形式的 lrts 可供选择，选择最佳治疗方法取决于技术方面、肝脏形态、肿瘤生物学和患者的症状。本文综述的目的是提供当前关于经皮消融、经动脉化疗栓塞和经动脉放射栓塞治疗 HCC 的疗效或姑息治疗的证据概述。还回顾了特殊情况，包括系统治疗与 lrts 的联合应用、桥接移植和降期的适应证和技术，以及 lrts 治疗合并大血管侵犯的 HCC 患者。
相似文献
1
Current locoregional therapies and treatment strategies in hepatocellular carcinoma.
Curr Oncol. 2020 Nov;27(Suppl 3):S144-S151. doi: 10.3747/co.27.7171. Epub 2020 Nov 1.
2
Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):34-41. doi: 10.1016/s1499-3872(13)60003-x.
3
Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
Cardiovasc Intervent Radiol. 2017 Mar;40(3):410-420. doi: 10.1007/s00270-016-1505-0. Epub 2016 Nov 29.
4
Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
Chin Clin Oncol. 2023 Apr;12(2):17. doi: 10.21037/cco-22-119. Epub 2023 Apr 18.
5
Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Hepatology. 2018 Jan;67(1):381-400. doi: 10.1002/hep.29485. Epub 2017 Nov 29.
6
Interventional radiology for hepatocellular carcinoma.
Minerva Gastroenterol Dietol. 2011 Sep;57(3):299-309.
7
Liver-directed therapy for hepatocellular carcinoma.
Abdom Radiol (NY). 2018 Jan;43(1):203-217. doi: 10.1007/s00261-017-1435-6.
8
Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma.
J Vasc Interv Radiol. 2017 Nov;28(11):1512-1519. doi: 10.1016/j.jvir.2017.06.016. Epub 2017 Jul 19.
9
Definitive locoregional therapy (LRT) versus bridging LRT and liver transplantation with wait-and-not-treat approach for very early stage hepatocellular carcinoma.
Diagn Interv Radiol. 2018 Jul;24(4):213-218. doi: 10.5152/dir.2018.17418.
10
Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
J Vasc Interv Radiol. 2019 Sep;30(9):1317-1324. doi: 10.1016/j.jvir.2019.03.024. Epub 2019 Jul 30.
引用本文的文献
1
Molecular MRI of T-cell immune response to cryoablation in immunologically hot . cold hepatocellular carcinoma.
JHEP Rep. 2024 Dec 4;7(3):101294. doi: 10.1016/j.jhepr.2024.101294. eCollection 2025 Mar.
2
Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Sep-Oct;16(5):e1990. doi: 10.1002/wnan.1990.
3
Radiological characteristics of hepatocellular carcinoma that achieved complete response after chemoembolization with drug-eluting beads for liver transplantation planning.
Einstein (Sao Paulo). 2023 Oct 27;21:eAO0307. doi: 10.31744/einstein_journal/2023AO0307. eCollection 2023.
4
Bridging locoregional treatment prior to liver transplantation for cirrhotic patients with hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis.
Ann Gastroenterol. 2023 Jul-Aug;36(4):449-458. doi: 10.20524/aog.2023.0812. Epub 2023 May 30.
5
Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario.
Can Liver J. 2021 Aug 9;4(3):257-274. doi: 10.3138/canlivj-2020-0039. eCollection 2021 Summer.
6
Hepatocellular Carcinoma with Gastrointestinal Involvement: A Systematic Review.
Diagnostics (Basel). 2022 May 19;12(5):1270. doi: 10.3390/diagnostics12051270.
7
Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC.
Cancers (Basel). 2021 Nov 18;13(22):5797. doi: 10.3390/cancers13225797.
8
Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice.
World J Hepatol. 2021 Sep 27;13(9):1132-1142. doi: 10.4254/wjh.v13.i9.1132.
9
Evaluation of Hepatocellular Carcinoma Patients: Interim Analysis of Cases from a Tertiary Referral Center in Craiova, Romania.
Curr Health Sci J. 2021 Jan-Mar;47(1):10-15. doi: 10.12865/CHSJ.47.01.02. Epub 2021 Mar 31.
10
Absent in melanoma 1-like (AIM1L) serves as a novel candidate for overall survival in hepatocellular carcinoma.
Bioengineered. 2021 Dec;12(1):2750-2762. doi: 10.1080/21655979.2021.1939636.
本文引用的文献
1
Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with Y in the SARAH Study.
Radiology. 2020 Sep;296(3):673-684. doi: 10.1148/radiol.2020191606. Epub 2020 Jun 30.
2
Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design.
Cancers (Basel). 2020 Jun 12;12(6):1557. doi: 10.3390/cancers12061557.
3
Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline.
Curr Oncol. 2020 Apr;27(2):e106-e114. doi: 10.3747/co.27.5891. Epub 2020 May 1.
4
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
5
Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
Transplantation. 2020 Jun;104(6):1136-1142. doi: 10.1097/TP.0000000000003174.
6
Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection.
Per Med. 2020 Mar;17(2):83-87. doi: 10.2217/pme-2018-0114. Epub 2020 Mar 11.
7
Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.
Cardiovasc Intervent Radiol. 2020 Mar;43(3):411-422. doi: 10.1007/s00270-019-02404-5. Epub 2020 Jan 6.
8
Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis.
Mol Clin Oncol. 2020 Jan;12(1):15-22. doi: 10.3892/mco.2019.1941. Epub 2019 Oct 31.
9
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
10
Modified Radiation Lobectomy: An Evolving Paradigm to Convert Patients to Liver Resection Candidacy.
Semin Intervent Radiol. 2019 Oct;36(4):343-348. doi: 10.1055/s-0039-1696648. Epub 2019 Oct 31.
Zotero 插件